Published in Clin Exp Immunol on December 01, 1982
RNase MRP cleaves the CLB2 mRNA to promote cell cycle progression: novel method of mRNA degradation. Mol Cell Biol (2004) 1.81
Impaired culture generated cytotoxicity with preservation of spontaneous natural killer-cell activity in cartilage-hair hypoplasia. J Clin Invest (1983) 0.88
Cord blood B cell differentiation. Synergistic effect of pokeweed mitogen and Staphylococcus aureus on in vitro differentiation of B cells from human neonates. Clin Exp Immunol (1984) 0.81
Cartilage-hair hypoplasia syndrome: increased apoptosis of T lymphocytes is associated with altered expression of Fas (CD95), FasL (CD95L), IAP, Bax, and Bcl2. J Clin Immunol (1999) 0.79
Cartilage hair hypoplasia: characteristics and orthopaedic manifestations. J Child Orthop (2015) 0.75
T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med (1981) 10.66
The functional relationship of the interleukins. J Exp Med (1980) 5.62
DWARFISM IN THE AMISH. II. CARTILAGE-HAIR HYPOPLASIA. Bull Johns Hopkins Hosp (1965) 4.23
Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes. Blood (1981) 2.58
Mechanism of T cell activation. II. Antigen- and lectin-dependent acquisition of responsiveness to TCGF is a nonmitogenic, active response of resting T cells. J Immunol (1981) 2.10
Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans. J Clin Invest (1981) 2.04
Relationship of cell cycle to recovery of IL 2 activity from human mononuclear cells, human and mouse T cell lines. J Immunol (1981) 1.88
In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. J Immunol (1978) 1.82
Human T lymphocyte/monocyte interaction in response to lectin: kinetics of entry into the S-phase. J Immunol (1981) 1.62
TCGF production for cloning and growth of functional human T lymphocytes. Scand J Immunol (1980) 1.50
Relationship between IL 2 synthesis and the proliferative response to PHA in different primary immunodeficiencies. J Immunol (1982) 1.45
Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proc Natl Acad Sci U S A (1979) 1.41
Ultrastructure and cytochemistry of human peripheral blood lymphocytes. Similarities between the cells of the third population and TG lymphocytes. Eur J Immunol (1980) 1.38
Chronic neutropenia and abnormal cellular immunity in cartilage-hair hypoplasia. N Engl J Med (1970) 1.27
Mammalian cell cycles need two random transitions. Cell (1980) 1.24
Human T cell growth factor. I. Optimal conditions for its production. J Immunol (1979) 1.17
Helper and suppressor-inducer activity of human T cells and their cloned progeny maintained in long-term culture. J Immunol (1981) 1.12
Immunologic studies of cartilage-hair hypoplasia in the Amish. Johns Hopkins Med J (1981) 1.07
Metabolic aspects of immunodeficiency disease. Semin Hematol (1980) 1.02
Cellular and humoral immmunity in cartilage-hair hypoplasia. Pediatr Res (1978) 1.01
A G1 rate model accounts for cell-cycle kinetics attributed to 'transition probability'. Nature (1980) 1.00
Induction of Fc gamma receptors on a subpopulation of human T lymphocytes by adenosine and impromidine, an H2-histamine agonist. Cell Immunol (1981) 0.97
Lymphocyte dysfunction in cartilage-hair hypoplasia: evidence for an intrinsic defect in cellular proliferation. J Immunol (1982) 0.91
Human T lymphocytes grown in T-cell growth factor: functional attributes in MLC, CML, PLT and allogeneic suppression. Immunology (1981) 0.83
T-cell growth factor-mediated proliferation of lymphocytes from a T-chronic lymphocytic leukaemia patient lacking mitogen and alloantigen responsiveness. Clin Exp Immunol (1981) 0.81
In vitro T- and B-cell reactivity in cartilage hair hypoplasia. Clin Exp Immunol (1978) 0.79
The biochemical basis of immunodeficiency disease. Eur J Pediatr (1980) 0.78
Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science (1987) 4.03
Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A (1978) 2.78
A laboratory medicine residency training program that includes clinical consultation and research. Arch Pathol Lab Med (1990) 2.07
Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med (1976) 2.04
Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest (1994) 1.88
Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res (1998) 1.82
Targeting bacteriophage to mammalian cell surface receptors for gene delivery. Hum Gene Ther (1998) 1.77
Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest (1994) 1.64
Restoration of in-vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency. Lancet (1975) 1.50
Granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: differential action on incisional wound healing. Surgery (1994) 1.49
Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J Clin Invest (1991) 1.48
Lymphocyte responsiveness to Pseudomonas aeruginosa in cystic fibrosis: Relationship to status of pulmonary disease in sibling pairs. J Pediatr (1978) 1.45
Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors. Hum Gene Ther (2001) 1.36
Immunoglobulin E in immunologic deficiency diseases. I. Relation of IgE and IgA to respiratory tract disease in isolated IgE deficiency, IgA deficiency, and ataxia telangiectasia. J Clin Invest (1972) 1.31
Cellular immunity to bacteria: impairment of in vitro lymphocyte responses to Pseudomonas aeruginosa in cystic fibrosis patients. Infect Immun (1977) 1.29
Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet (1992) 1.25
Mitogenic signals for platelet-derived growth factor isoforms in liver fat-storing cells. Am J Physiol (1991) 1.24
Keratinocyte growth factor is a growth factor for mammary epithelium in vivo. The mammary epithelium of lactating rats is resistant to the proliferative action of keratinocyte growth factor. Am J Pathol (1994) 1.21
The breastmilk macrophage: a potential vehicle for immunoglobulin transport. J Reticuloendothel Soc (1977) 1.18
Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost (2013) 1.17
Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr (1988) 1.16
Keratinocyte growth factor induces pancreatic ductal epithelial proliferation. Am J Pathol (1994) 1.14
Defective cellular immunity to gram-negative bacteria in cystic fibrosis patients. Infect Immun (1979) 1.14
Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int J Cancer (1999) 1.12
Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J (1999) 1.11
Cartilage hair hypoplasia: immunological aspects and their clinical implications. Clin Immunol Immunopathol (1986) 1.11
Differential regulation of the expression of proteinases/antiproteinases in fibroblasts. Effects of interleukin-1 and platelet-derived growth factor. J Biol Chem (1991) 1.10
Staphylococcus aureus Cowan I-induced immunoglobulin production in human cord blood lymphocytes. J Immunol (1980) 1.08
Immunologic studies of cartilage-hair hypoplasia in the Amish. Johns Hopkins Med J (1981) 1.07
Pharmacological modification of immunoregulatory T lymphocytes . II. Modulation of T lymphocyte cell surface characteristics. Clin Exp Immunol (1982) 1.07
Increased circulating IgE in trichinosis. Ann Intern Med (1971) 1.07
Ultrastructural localization of a platelet-derived growth factor/v-sis-related protein(s) in cytoplasm and nucleus of simian sarcoma virus-transformed cells. Proc Natl Acad Sci U S A (1987) 1.06
FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. Mol Ther (2000) 1.06
Immunoglobulin E in bronchiolitis. Pediatrics (1972) 1.05
Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology (1996) 1.04
Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency. J Clin Invest (1976) 1.03
A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg (1994) 1.03
Keratinocyte growth factor causes proliferation of urothelium in vivo. J Urol (1995) 1.02
Metabolic aspects of immunodeficiency disease. Semin Hematol (1980) 1.02
Reversal of impaired wound healing in irradiated rats by platelet-derived growth factor-BB. Am J Surg (1989) 0.99
Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1982) 0.99
Cytotoxic factors secreted by cells infected by human immunodeficiency virus type I. AIDS Res Hum Retroviruses (1987) 0.98
Spectrum of IgG2 subclass deficiency in children with recurrent infections: prospective study. J Pediatr (1986) 0.97
Induction of Fc gamma receptors on a subpopulation of human T lymphocytes by adenosine and impromidine, an H2-histamine agonist. Cell Immunol (1981) 0.97
Evolution of sequence divergence among human immunodeficiency virus type 1 isolates derived from a blood donor and a recipient. Pediatr Res (1993) 0.96
Pharmacological modification of immunoregulatory T lymphocytes. I. Effect of adenosine, H1 and H2 histamine agonists upon T lymphocyte regulation of B lymphocyte differentiation in vitro. Clin Exp Immunol (1982) 0.96
Growth factors and cytokines in hair follicle development and cycling: recent insights from animal models and the potentials for clinical therapy. Mol Med Today (1996) 0.95
IgE in immunodeficiency. Am J Pathol (1972) 0.95
A comparison of three radioimmunoassay techniques for the measurement of serum IgE. J Immunol (1973) 0.95
Demonstration of adenosine receptor on human lymphocytes in vitro and its possible role in the adenosine deaminase-deficient form of severe combined immunodeficiency. Clin Immunol Immunopathol (1978) 0.94
Subnormal serum concentrations of IgG2 in children with frequent infections associated with varied patterns of immunologic dysfunction. J Pediatr (1990) 0.94
Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res (1999) 0.93
Efficacy and safety of high-dose intravenous immune globulin therapy for antibody deficiency syndromes. Am J Med (1984) 0.92
Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res (1998) 0.92
Neu differentiation factor upregulates epidermal migration and integrin expression in excisional wounds. J Clin Invest (1995) 0.92
Matrix-enabled gene transfer for cutaneous wound repair. Wound Repair Regen (2001) 0.91
Changes in lymphocyte reactivity to Pseudomonas aeruginosa in hospitalized patients with cystic fibrosis. Am Rev Respir Dis (1981) 0.91
Targeting DNA to cells with basic fibroblast growth factor (FGF2). J Biol Chem (1996) 0.91
Lymphocyte dysfunction in cartilage-hair hypoplasia: evidence for an intrinsic defect in cellular proliferation. J Immunol (1982) 0.91
Impaired immunoregulation in systemic lupus erythematosus: defective adenosine-induced suppressor T lymphocyte generation. J Immunol (1983) 0.91
Collagen-embedded platelet-derived growth factor DNA plasmid promotes wound healing in a dermal ulcer model. J Surg Res (2000) 0.91
Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum Gene Ther (2000) 0.90
Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke. Eur Neurol (1998) 0.90
Impaired culture generated cytotoxicity with preservation of spontaneous natural killer-cell activity in cartilage-hair hypoplasia. J Clin Invest (1983) 0.88
The risk of AIDS: psychologic impact on the hemophilic population. Gen Hosp Psychiatry (1987) 0.86
Clinical relevance of granulocytotoxic antibodies in human transplantation. Transplant Proc (1977) 0.86
Keratinocyte growth factor causes cystic dilation of the mammary glands of mice. Interactions of keratinocyte growth factor, estrogen, and progesterone in vivo. Am J Pathol (1994) 0.86
Lymphocyte enzyme deficiencies and the metabolic basis of immunodeficiency disease. Clin Haematol (1977) 0.86
Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein. Int J Cancer (1998) 0.86
Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects. J Clin Invest (1993) 0.85
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost (2014) 0.85
Increased creatine kinase MB in the absence of acute myocardial infarction. Clin Chem (1986) 0.84
The metabolism of IgE in patients with immunodeficiency states and neoplastic conditions. J Clin Invest (1977) 0.84
Acceleration of tissue repair by transforming growth factor beta 1: identification of in vivo mechanism of action with radiotherapy-induced specific healing deficits. Surgery (1993) 0.84
Actions of platelet-derived growth factor isoforms in mesangial cells. J Cell Physiol (1994) 0.84
A hereditary immunodeficiency characterized by CD8+ T lymphocyte deficiency and impaired lymphocyte activation. Clin Exp Immunol (1992) 0.84
Tissue generation with growth factors. Surgery (1993) 0.83
Platelet-derived growth factor induces phosphorylation of a 64-kDa nuclear protein. J Biol Chem (1989) 0.83
Boundary layer infusion of basic fibroblast growth factor accelerates intimal hyperplasia in endarterectomized canine artery. J Surg Res (1997) 0.82
Differential acceleration of healing of surgical incisions in the rabbit gastrointestinal tract by platelet-derived growth factor and transforming growth factor, type beta. Surgery (1990) 0.82
What is a cure and how do we get there? Haemophilia (2004) 0.82
Influence of cystic fibrosis plasma on lymphocyte responses to Pseudomonas aeruginosa in vitro. Pediatr Res (1981) 0.81
Pancreatitis, malabsorption, and IgA deficiency in a child with diabetes. J Pediatr (1971) 0.81
Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein. Haemophilia (2014) 0.81
Abnormal platelet aggregation in severe combined immunodeficiency disease with adenosine deaminase deficiency. Br J Haematol (1978) 0.80
Natural cytotoxicity in immunodeficiency diseases: preservation of natural killer activity and the in vivo appearance of radioresistant killing. Hum Immunol (1986) 0.80
Use of intravenous immune globulin in pregnant women with common variable hypogammaglobulinemia. Am J Med (1984) 0.80
Lymphocyte responses of human neonates to bacterial antigens. Cell Immunol (1981) 0.80
Chick limb bud mesodermal cell chondrogenesis: inhibition by isoforms of platelet-derived growth factor and reversal by recombinant bone morphogenetic protein. Exp Cell Res (1992) 0.79
Anti-IgA antibody associated reactions to intravenous gammaglobulin in a patient who tolerated intramuscular gammaglobulin. Ann Allergy (1986) 0.79
Long-term immunological reconstitution by peripheral blood leucocytes in severe combined immune deficiency disease: implications for the role of mature lymphocytes in histocompatible bone marrow transplantation. Clin Exp Immunol (1986) 0.79